DrugPatentWatch Database Preview
TRINTELLIX Drug Profile
Which patents cover Trintellix, and when can generic versions of Trintellix launch?
Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and ninety-nine patent family members in forty-one countries.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vortioxetine hydrobromide profile page.
Summary for TRINTELLIX
| International Patents: | 199 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 104 |
| Clinical Trials: | 6 |
| Patent Applications: | 55 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TRINTELLIX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TRINTELLIX |
| DailyMed Link: | TRINTELLIX at DailyMed |
Generic Entry Opportunity Date for TRINTELLIX
Generic Entry Date for TRINTELLIX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for TRINTELLIX
| 1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl)piperazine monohydrobromide |
| 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine hydrobromide |
| 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine-hbr |
| 1-[2-[(2,4-dimethylphenyl)thio]phenyl]piperazine hydrobromide |
| 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine hydrobromide |
| 2796AH |
| 4-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide |
| 4-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazin-1-ium bromide |
| 960203-27-4 |
| AB0165485 |
| AC-28325 |
| AKOS016340374 |
| Brintellix |
| Brintellix (TN) |
| C18H22N2S.BrH |
| CHEBI:76015 |
| CHEMBL2107387 |
| CS-1472 |
| D10185 |
| EBD3080710 |
| FT-0696676 |
| HG-0011 |
| HY-15414A |
| KB-81459 |
| Lu AA 21004 hydrobromide;Lu AA21004 hydrobromide |
| Lu AA 21004|||1-[2-[(2,4-dimethylphenyl)thio]phenyl]-piperazine hydrobromide |
| Lu AA21004 (HBr) |
| Lu-AA-21004 |
| Lu-AA21004-(HBr) |
| MFCD22383961 |
| MolPort-023-298-793 |
| Piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-, hydrobromide (1:1) |
| s8021 |
| SC-95551 |
| SCHEMBL237653 |
| TKS641KOAY |
| UNII-TKS641KOAY |
| VNGRUFUIHGGOOM-UHFFFAOYSA-N |
| Vortioxetine (hydrobromide) |
| Vortioxetine (Lu AA21004) HBr |
| Vortioxetine (Lu AA21004) hydrobromide |
| Vortioxetine HBr |
| Vortioxetine hydrobromide |
| Vortioxetine hydrobromide (JAN/USAN) |
| Vortioxetine hydrobromide [USAN] |
| vortioxetine monohydrobromide |
| W-5911 |
US Patents and Regulatory Information for TRINTELLIX
Paragraph IV (Patent) Challenges for TRINTELLIX
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mgand 20 mg | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for TRINTELLIX
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Korea | 20130133078 | ➤ Try a Free Trial |
| Japan | 2011503125 | ➤ Try a Free Trial |
| Iceland | 8806 | ➤ Try a Free Trial |
| Japan | 3896116 | ➤ Try a Free Trial |
| Argentina | 061481 | ➤ Try a Free Trial |
| Slovenia | 1436271 | ➤ Try a Free Trial |
| Iceland | 2578 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for TRINTELLIX
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 14/022 | Ireland | ➤ Try a Free Trial | PRODUCT NAME: VORTIOXETINE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/891 20131220 |
| 2014000049 | Germany | ➤ Try a Free Trial | PRODUCT NAME: VORTIOXETIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SAEUREADDITIONSSALZ DAVON; REGISTRATION NO/DATE: EU/1/13/891 20131218 |
| C0033 | France | ➤ Try a Free Trial | PRODUCT NAME: VORTIOXETINE OU L'UN DE SES SELS D'ADDITION D'ACIDE PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/891 20131218 |
| 0140012 00108 | Estonia | ➤ Try a Free Trial | PRODUCT NAME: VORTIOKSETIIN;REG NO/DATE: K(2013)9715 LOPLIK 20.12.2013 |
| 2014 00030 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: VORTIOXETIN ELLER FARMACEUTISK ACCEPTABLE SYREADDITIONSSALTE DERAF, HERUNDER VORTIOXETINHYDROBROMID; REG. NO/DATE: EU/1/13/891 20131218 |
| 00652 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: VORTIOXETINE OF EEN; REGISTRATION NO/DATE: EU/1/13/891/001-036 20131218 |
| 397 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: VORTIOXETINE OU UN SEL D ADDITION D ACIDE DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
